950769-51-4 Usage
Description
N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea is a complex urea derivative featuring isoxazole, imidazo[2,1-b]benzothiazole, and phenyl groups. This chemical compound has a distinctive molecular structure that positions it as a candidate for pharmaceutical research and drug development. Its potential biological activity suggests it may be useful in treating specific medical conditions or as a research tool for studying biological processes. Further research is required to fully explore its properties and applications.
Uses
Used in Pharmaceutical Research:
N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea is used as a research compound for exploring its potential biological activity and therapeutic effects. Its unique molecular structure makes it a valuable asset in the discovery of new drugs and treatments for various medical conditions.
Used in Drug Development:
In the pharmaceutical industry, N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N'-[4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)phenyl]urea is utilized as a lead compound in the development of new medications. Its properties may contribute to the creation of innovative therapies that address unmet medical needs.
Check Digit Verification of cas no
The CAS Registry Mumber 950769-51-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,0,7,6 and 9 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 950769-51:
(8*9)+(7*5)+(6*0)+(5*7)+(4*6)+(3*9)+(2*5)+(1*1)=204
204 % 10 = 4
So 950769-51-4 is a valid CAS Registry Number.
950769-51-4Relevant articles and documents
Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor
Chao, Qi,Sprankle, Kelly G.,Grotzfeld, Robert M.,Lai, Andiliy G.,Carter, Todd A.,Velasco, Anne Marie,Gunawardane, Ruwanthi N.,Cramer, Merryl D.,Gardner, Michael F.,James, Joyce,Zarrinkar, Patrick P.,Patel, Hitesh K.,Bhagwat, Shripad S.
experimental part, p. 7808 - 7816 (2010/09/08)
Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharma
Imidazolothiazole compounds for the treatment of disease
-
Page/Page column 41, (2008/06/13)
Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
